Compare Globus Medical Inc. Class A Common Stock (GMED) vs Invesco S&P 500 High Div Low Volatility ETF (SPHD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Globus Medical Inc. Class A Common Stock vs Invesco S&P 500 High Div Low Volatility ETF — how do they compare? Globus Medical Inc. Class A Common Stock trades at $76.58 (market cap $10.25B), while Invesco S&P 500 High Div Low Volatility ETF trades at $49.87 (market cap $3.20B). The key difference: Globus Medical Inc. Class A Common Stock is far larger — about 3.2× Invesco S&P 500 High Div Low Volatility ETF's market cap, and Invesco S&P 500 High Div Low Volatility ETF is more actively traded (2,286,453 versus 1,059,528). Which is the better fit depends on your goals — on Pluang, investors hold Globus Medical Inc. Class A Common Stock for 0 Days and Invesco S&P 500 High Div Low Volatility ETF for 126 Days on average.
| GMED | SPHD | |
|---|---|---|
Market Cap | $10.25B | $3.20B |
Volume | 1,059,528 | 2,286,453 |
Sector | Health | — |
52-Week High | $96.82 | $53.55 |
52-Week Low | $58.33 | $46.96 |
Typical Hold Time | 0 Days | 126 Days |
Enterprise Value | $9.76B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.
GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.
SPHD, the Invesco S&P 500 High Dividend Low Volatility ETF, trades at $49.29, up 0.1% on the day. Technical indicators show a mixed picture with a bullish overall signal but bearish moving averages, while the RSI suggests mild overbought conditions. The ETF focuses on high dividend yields and low volatility, attracting income-focused investors, though recent news highlights performance comparisons with peers like SCHD.
The outlook for SPHD hinges on its dividend strategy amid market volatility. Opportunities include steady income for retirees, but risks involve underperformance versus growth-focused ETFs and sensitivity to interest rate changes. Investors should weigh the trade-off between yield and total return potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Globus Medical Inc. Class A Common Stock
Globus Medical, Inc. develops and manufactures medical devices for treating musculoskeletal disorders, including spine, orthopedic trauma, and neurosurgical products. It operates in US and internationally, serving surgeons and healthcare providers.
Read more on GMED →About Invesco S&P 500 High Div Low Volatility ETF
The fund generally will invest at least 90% of its total assets in the securities that comprise the underlying index. Strictly in accordance with its guidelines and mandated procedures, S&P Dow Jones Indices LLC (the “index Provider”) compiles, maintains and calculates the underlying index, which is designed to measure the performance of 50 least volatile high yielding constituents of the S&P 500 ® Index in the past year.
Read more on SPHD →
